Novartis backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer.

Novartis backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer. https://ift.tt/4YgF2tZ